Hochhold, Stefanie B.
Venture Capital and Corporate Venture Capital in Financing Biotech Companies
Year of Publication: 2012
Frankfurt am Main, Berlin, Bern, Bruxelles, New York, Oxford, Wien, 2012. 159 pp.,19 tables
ISBN 978-3-631-61874-5 pb. (Softcover)
Weight: 0.220 kg, 0.485 lbs
- SFR 43.00
- €* 37.95
- €** 39.10
- € 35.50
- £ 28.00
- US$ 46.95
» Currency of invoice
* includes VAT – valid for Germany and EU customers without VAT Reg No
** includes VAT – only valid for Austria
This book offers insights into three different aspects of financing companies with venture capital (VC) and corporate venture capital (CVC) using three independent and specific datasets. First the study analyses particular VC financing mechanisms depending on differences in the national institutional framework and the experience of the VC investor. The question whether the actual value-adding ability of VC investments in contrast to CVC investments differs from a portfolio company’s perspective is discussed in the second chapter. Finally, the time-dependent performance of CVC investments is analysed.
Contents: VC financing mechanisms by differences in the national institutional framework and the experience of the VC investor – Value-adding ability of VC investments in contrast to CVC investments from a portfolio company’s perspective – Time-dependent performance of CVC investments.
About the author(s)/editor(s)
Stefanie B. Hochhold graduated in Business Administration at Ludwig-Maximilians-University (LMU) in Munich in 2006 and worked as a research and teaching assistant at the Institute of Capital Market Research and Finance at LMU. Since 2009 she holds a Master of Business Research (MBR) and received her PhD degree (Dr. oec. publ.) in 2011.
European University Studies. Series 5: Economics and Management. Vol. 3404